Every Form 4 that Anterix Inc. (ATEX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATEX filings page.
Anterix Inc. (ATEX) President and CEO Scott A. Lang sold 15,000 shares of common stock on September 21, 2026, at $80 per share. The sale was made under a Rule 10b5-1(c) trading plan adopted June 22, 2026. After the transaction, Lang directly held 26,470 shares.
Anterix Inc. (ATEX) reported that President and CEO, and director, Scott A. Lang sold 15,000 shares of common stock on September 21, 2026 in a sale characterized as an open market or private transaction at $80.00 per share. Following this transaction, he directly holds 26,470 shares of Anterix common stock, and no Rule 10b5-1 trading plan is reported in connection with this sale.
Anterix Inc. (ATEX) reported that officer Martin Heather, Chief Marketing Officer and Chief of Staff, disposed of common stock in two transactions. On September 9, 2026, 3,465 shares were withheld to satisfy tax obligations upon partial vesting of restricted stock units. On September 10, 2026, 8,064 shares were sold in an open-market or private transaction at a weighted average price of $84.2011 per share, with individual sale prices ranging from $84.00 to $84.468. No Rule 10b5-1 trading plan is indicated.
Anterix Inc. (ATEX) reported that Chief Legal Officer & Corp Sec Gena L. Ashe exercised stock options for 6,833 shares of common stock at $34.96 per share on September 8, 2026. The exercise was handled on a cashless basis, with 2,769 shares withheld to cover the exercise price and income tax obligations, and the remaining shares largely sold in open-market transactions.
Anterix Inc. (ATEX) director Leslie B. Daniels reported selling 2,500 shares of common stock on September 10, 2026 in an open-market or private transaction at a weighted average price of $83.83 per share, with individual sale prices ranging from $84.25 to $83.55.
After this sale, Daniels directly held 43,477 shares, and also had indirect holdings of 2,000 shares through an IRA and 5,000 shares through a 401K.
Anterix Inc. (ATEX) reported that Chief Legal Officer and Corporate Secretary Gena L. Ashe sold an aggregate of 4,357 shares of Anterix common stock on September 8, 2026, in two open-market or private transactions at $85.44 per share. No Rule 10b5-1 trading plan is reported for these sales.
Anterix Inc. (ATEX) director Leslie B. Daniels reported selling a total of 10,100 shares of Anterix common stock in open-market transactions on September 3–4, 2026. Reported prices included $87.15, $87.3103 and $86.50 per share, with some prices stated as weighted averages over intraday ranges.
After these transactions, Daniels was reported as holding 2,000 shares indirectly through an IRA and 5,000 shares indirectly through a 401(k) plan as of September 3, 2026. No Rule 10b5-1 trading plan was reported for these sales.
Anterix Inc. (ATEX) reported that Chief Reg & Comm Officer Christopher Guttman-McCabe exercised a stock option for 40,000 shares of common stock at an exercise price of $37.42 per share. The option was fully vested. The exercise was paid on a cashless basis, with the issuer withholding 16,561 shares to cover the exercise price and related income tax withholding and remittance obligations. On the same date, the reporting person sold an aggregate of 23,439 shares of common stock in open-market transactions at weighted average prices ranging from about $94.22 to $90.06 per share. The transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan.
Anterix Inc. (ATEX) director and Executive Chairman Thomas R. Kuhn reported an option exercise and related share sales. On August 24, 2026, he exercised stock options for 10,000 shares of common stock at an exercise price of $33.62 per share, reducing that option position to 48,998 shares. He then sold an aggregate of 10,000 common shares in multiple open-market transactions on the same date at weighted-average prices between the high $80s and low $90s per share, plus an additional 1,654 shares sold on June 18, 2026 at $79.52 per share to cover tax withholding on RSU settlements. Earlier, on May 20, 2026, he received a grant of 2,791 restricted stock units, each representing one share of common stock, vesting in full on the earlier of May 20, 2027 or Anterix’s next annual stockholder meeting.
Anterix Inc. (ATEX) director William Heard reported a bona fide gift of 5,400 shares of Common Stock on 2026-08-19. The filing notes this represents a charitable donation of shares to a Donor Advised Fund. Following the gift, he directly holds 3,965 shares of Common Stock.
The filing also reports 1,670,338 shares of Common Stock held indirectly through certain investment funds and/or accounts for which Heard Capital LLC serves as investment manager. William Heard is the ultimate beneficial owner of Heard Capital LLC, and both Heard Capital LLC and William Heard disclaim beneficial ownership of these indirectly held securities for Section 16 purposes, except to the extent of their pecuniary interest.
Anterix Inc. (ATEX) director William Heard, through entities associated with Heard Capital LLC, reported a sale of 46,400 shares of Common Stock on 2026-08-14. The weighted average sale price was $90.1098 per share, with individual trades executed between $89.9942 and $90.115. After this transaction, investment funds and/or accounts for which Heard Capital LLC serves as investment manager held 1,670,338 shares reported as indirect ownership, and 9,365 shares were reported as directly owned. The reporting person and Heard Capital LLC each disclaim beneficial ownership of these securities for Section 16 purposes except to the extent of pecuniary interest.
Anterix Inc. President and CEO Scott A. Lang reported open-market sales of 35,057 shares of Common Stock on August 14, 2026. The reported per-share prices include 800 shares at $91.69, plus additional blocks sold at weighted average prices that reflect multiple trades within specified price ranges.
Anterix Inc. insider Christopher Guttman-McCabe, Chief Reg & Comm Officer, reported multiple open-market sales of common stock on June 15, 2026 totaling 122,852 shares at weighted average prices between $78.7255 and $84.4012 per share. A Form 4/A amendment corrects the originally reported amounts, reflecting an additional 31,415 shares sold and revised beneficial ownership figures.
Director William Heard of Anterix Inc. reported a bona fide gift of 1,887 shares of Common Stock on December 29, 2025, as a charitable donation to a Donor Advised Fund. After this transfer, he holds 9,365 shares directly and 1,716,738 shares indirectly through funds managed by Heard Capital LLC, for which beneficial ownership is disclaimed except to the extent of his pecuniary interest.
Heard William reported acquisition or exercise transactions in this Form 4 filing.
Anterix Inc. director William Heard received a grant of 1,598 shares of Common Stock on August 4, 2026 at no cost. These restricted shares will vest on the earlier of the 2027 annual meeting of shareholders and August 4, 2027, under a Restricted Stock Agreement. Following the award, he directly holds 11,252 shares. A separate reported position shows 1,716,738 shares held by investment funds or accounts managed by Heard Capital LLC, for which he is the ultimate beneficial owner; both he and Heard Capital LLC disclaim beneficial ownership of those shares except to the extent of any pecuniary interest.
ALTMAN JEFFREY A reported acquisition or exercise transactions in this Form 4 filing.
Anterix Inc. director and ten percent owner Jeffrey A. Altman reported a grant of 1,598 shares of common stock on August 4, 2026 as compensation for his services as a non-employee director. The award will vest on the earlier of the 2027 annual shareholder meeting and August 4, 2027 under a Restricted Stock Agreement.
After this grant, Altman reported 124,492 shares of common stock held directly and 5,411,776 shares held indirectly through Owl Creek funds advised by Owl Creek Asset Management, L.P. Altman and the investment manager each disclaim beneficial ownership beyond their pecuniary interests in these securities.
YAZDI MAHVASH reported acquisition or exercise transactions in this Form 4 filing.
Anterix Inc. director Mahvash Yazdi received a grant of 1,598 shares of common stock on August 4, 2026, as a restricted stock award at $0.00 per share. These shares vest on the earlier of the 2027 annual shareholder meeting or August 4, 2027. Following the grant, she directly holds 21,005 shares, with additional indirect holdings of 250 shares through a family trust, where she disclaims beneficial ownership beyond her pecuniary interest, and 750 shares through a 401(k) plan. The transaction is reported as not pursuant to a Rule 10b5-1 trading plan.
Fleischhauer Mark reported acquisition or exercise transactions in this Form 4 filing.
Anterix Inc. director Mark Fleischhauer received a grant of 1,598 shares of common stock as a stock award. The shares vest on the earlier of the company’s 2027 Annual Meeting of shareholders and August 4, 2027, under a Restricted Stock Agreement, bringing his direct holdings to 14,367 shares.
Anterix Inc. director Leslie B. Daniels reported receiving a grant of 1,598 shares of common stock on August 4, 2026 as a restricted stock award. These shares will vest on the earlier of the 2027 Annual Meeting of shareholders and August 4, 2027, under a Restricted Stock Agreement.
Following this award, Daniels directly holds 56,077 Anterix shares, with additional indirect holdings of 2,000 shares by IRA and 5,000 shares by 401K. The award is a compensation-related acquisition and was not designated as made under a Rule 10b5-1 trading plan.
Anterix Inc. Chief Financial Officer Elena Marquez reported a tax-related share disposition. On 2026-07-13, 231 shares of common stock were withheld by the issuer at $100.96 per share to satisfy withholding obligations tied to partial vesting and settlement of restricted stock units. Following this non-market, tax-withholding disposition, Marquez holds 18,156 shares of Anterix common stock directly.
Anterix Inc. Chief Reg & Comm Officer Christopher Guttman-McCabe reported a Form 4 transaction involving a tax-withholding disposition of 1,516 shares of common stock at $100.96 per share on July 13, 2026. The shares were withheld by the company to satisfy withholding obligations related to the partial vesting and settlement of restricted stock units. After this withholding, he directly holds 76,291 shares of Anterix common stock.
Anterix Inc. executive Christopher Guttman-McCabe updated his reported stock option holdings to correct a previously misreported balance. The amended disclosure shows a fully vested stock option to purchase 50,876 shares of common stock at an exercise price of $34.40 per share, expiring on October 21, 2030. No new option grants, exercises, sales, or other transactions are reported; only the number of securities held was corrected.
Anterix Inc. director and President & CEO Scott A. Lang reported an open-market sale of company stock. On June 18, 2026, he sold 170 shares of Anterix common stock at an average price of $80.25 per share. After this transaction, he directly holds 76,527 shares of common stock, so the sale reflects only a small portion of his reported direct position.
Anterix Inc.’s Chief Financial Officer Elena Marquez reported an open‑market sale and an option exercise involving the company’s common stock. On June 17, 2026, she sold 4,291 shares at $79.50 per share and exercised stock options for 1,226 shares at $40.00 per share. Following these transactions, she directly holds 18,387 shares of common stock and 2,454 stock options. The option grant referenced in the filing vests in three equal annual installments beginning on October 4, 2025.
Anterix Inc. Chief Regulatory & Communications Officer Christopher Guttman-McCabe reported a combination of option exercises and share sales in Anterix common stock. On June 15, 2026, he exercised stock options to acquire a total of 122,852 common shares at strike prices between $25.75 and $49.39 per share.
On the same date, he executed open-market sales totaling 91,437 common shares at weighted average prices ranging from about $81.32 to $84.29 per share, across multiple price ranges noted in the footnotes. Following these transactions, one reported entry shows he directly owned 77,807 common shares. The filing also states that the option shares involved in these exercises were fully vested.
Anterix Inc. Chief Legal Officer & Corporate Secretary Gena L. Ashe exercised stock options and sold common stock in a series of transactions dated June 15, 2026. She exercised options covering 29,368 shares of common stock at strike prices of $34.96 and $49.39 per share.
To pay the exercise prices and related taxes on a cashless basis, the issuer withheld a total of 15,657 shares at $82.50 per share, which the filing clarifies did not involve open‑market sales. Ashe also completed open‑market sales totaling 17,711 shares at weighted average prices of about $81.04 and $82.14 per share. One reported sale left her with 9,531 shares held directly.
Anterix Inc. President and CEO Scott A. Lang exercised stock options and settled related obligations in shares. On June 15, 2026, he exercised options to acquire 63,788 shares at $30.99 per share and 74,530 shares at $34.96 per share. The company withheld 39,621 and 48,470 shares, respectively, to pay the exercise prices and cover income tax withholding, which the filing states did not involve any open market sales.
Anterix Inc. director Mark Fleischhauer reported an open-market sale of 3,500 shares of Common Stock on June 15, 2026 at an average price of $79.8294 per share. Following this transaction, he directly holds 12,769 Anterix common shares.
Anterix Inc. director Mahvash Yazdi reported selling 7,000 shares of Common Stock at $80.00 per share in an open-market transaction. After this sale, she directly holds 19,407 shares. She also indirectly holds 750 shares through a 401(k) and 250 shares through the Yazdi Family Trust, where she serves as trustee and disclaims beneficial ownership beyond her pecuniary interest.
Anterix Inc. Chief Legal Officer & Corporate Secretary Gena L. Ashe reported a routine tax-related share withholding. On the transaction date, 2,501 shares of common stock were withheld by Anterix to cover withholding obligations tied to a partial vesting and settlement of restricted stock units, at an implied value of $60.00 per share. Following this non-market transaction, Ashe directly holds 13,531 shares of Anterix common stock.
Anterix Inc. reported that President and CEO Scott A. Lang received new equity awards. He was granted 18,210 shares of Common Stock as restricted stock units and now directly holds 26,470 common shares after this award.
Lang also received stock options for 72,839 shares of Common Stock at an exercise price of $60.90 per share, expiring on May 20, 2036. Both the RSUs and the options vest over three years, with one-third vesting on May 20, 2027 and the remaining portions vesting in equal quarterly installments through May 20, 2029.
Anterix Inc. reported that Chief Legal Officer & Corporate Secretary Gena L. Ashe received equity awards as compensation. She was granted 3,694 restricted stock units, increasing her direct common stock holdings to 16,032 shares. She also received options for 17,453 shares at an exercise price of $60.90 per share, expiring on May 20, 2036. Both the RSUs and options vest over three years, with one-third vesting on May 20, 2027 and the remainder vesting in equal quarterly installments through May 20, 2029.
Anterix Inc. reported that Chief Reg & Comm Officer Christopher Guttman-McCabe received equity awards as part of his compensation. He was granted 4,926 restricted stock units, each representing one share of common stock, vesting over three years starting on May 20, 2027.
He also received options on 23,271 shares of common stock at an exercise price of $60.90, vesting on the same three-year schedule and expiring on May 20, 2036. Following these awards, he directly holds 46,392 shares of common stock.
Anterix Inc. reported a routine equity compensation grant to its Chief Financial Officer, Elena Marquez. She received 3,694 shares of common stock in the form of restricted stock units, which vest over three years starting on May 20, 2027.
Marquez also received stock options for 17,453 shares of common stock at an exercise price of $60.90 per share, expiring on May 20, 2036. These options vest on the same schedule, with one-third vesting on May 20, 2027 and the remainder vesting quarterly through May 20, 2029. After the RSU grant, she directly holds 21,452 common shares.
Anterix Inc. Chief Marketing Officer and Chief of Staff Heather Martin received new equity compensation in the form of restricted stock units and stock options. She was granted 3,694 RSUs representing the right to receive the same number of Anterix common shares, bringing her direct common stock holdings to 38,272 shares after the award.
She was also granted stock options for 17,453 shares of common stock at an exercise price of $60.90 per share, expiring on May 20, 2036. Both the RSUs and the options vest over three years, with one-third vesting on May 20, 2027 and the remaining two-thirds vesting in equal quarterly installments on specified dates through May 20, 2029. These are compensation-related grants, not open-market purchases or sales.
Anterix Inc. Chief Legal Officer and Corporate Secretary Gena L. Ashe reported a routine tax-withholding transaction involving company stock. On May 18, 2026, 1,028 shares of Anterix common stock were withheld by the company at $57.06 per share to satisfy withholding obligations tied to the partial vesting and settlement of restricted stock units.
Following this non-market disposition, Ashe directly holds 12,338 shares of Anterix common stock. Because the shares were withheld for taxes rather than sold on the open market, the filing reflects a compensation-related event rather than an active investment decision.
Anterix Inc.'s Chief Reg & Comm Officer Christopher Guttman-McCabe reported a routine tax-related share disposition. On the RSU vesting date, 1,426 shares of common stock were withheld by Anterix at $57.06 per share to satisfy withholding obligations tied to the partial vesting and settlement of restricted stock units.
This was not an open-market sale but an automatic tax-withholding disposition connected to equity compensation. After this transaction, Guttman-McCabe directly holds 41,466 shares of Anterix common stock, indicating he retains a meaningful equity stake in the company.
Anterix Inc. Chief Financial Officer Elena Marquez reported a small, routine tax-withholding transaction. On the disposition date, 271 shares of common stock were withheld by the company at $56.62 per share to satisfy tax obligations tied to a partial vesting of a restricted stock unit award. After this non-market transaction, she directly holds 17,758 shares of Anterix common stock.
Anterix Inc. Chief Legal Officer and Corporate Secretary Gena L. Ashe reported option-related transactions in company stock. On March 3, 2026, Ashe exercised stock options for 12,427 shares, converting them into an equal number of Anterix common shares at an exercise price of $27.83 per share.
On the same date, 12,427 common shares were disposed of in a transaction coded as a tax-withholding event, using shares to satisfy the exercise price or tax obligations. Following these transactions, Ashe directly owned 13,366 shares of Anterix common stock.
Anterix Inc. (ATEX) Chief Legal Officer and Corporate Secretary Gena L. Ashe reported a stock sale in a Form 4 filing. On 11/18/2025, she sold 6,564 shares of Anterix common stock at a price of $21.07 per share. After this transaction, she beneficially owns 13,366 shares of Anterix common stock directly.
Anterix Inc. (ATEX) disclosed insider equity activity by its CFO. On 09/29/2025, the officer received 11,405 restricted stock units. The grant vests 1/3 on September 29, 2026, with the remainder vesting in two equal annual installments thereafter.
On 10/04/2025, 404 shares were withheld at $22.55 to satisfy tax obligations tied to a partial RSU vest and settlement. Following these transactions, the officer directly owned 18,029 common shares.